Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Shanghai Medicilon's share price for the quarter that ended in Mar. 2026 was ¥62.4. Shanghai Medicilon's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 134 Mil. Therefore, Shanghai Medicilon's market cap for the quarter that ended in Mar. 2026 was ¥8,384 Mil.
Shanghai Medicilon's quarterly market cap
declined
from Sep. 2025 (¥9,329 Mil) to Dec. 2025 (¥7,577 Mil) but then
increased
from Dec. 2025 (¥7,577 Mil) to Mar. 2026 (¥8,384 Mil).
Shanghai Medicilon's annual market cap
declined
from Dec. 2023 (¥9,209 Mil) to Dec. 2024 (¥4,063 Mil) but then
increased
from Dec. 2024 (¥4,063 Mil) to Dec. 2025 (¥7,577 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Shanghai Medicilon's Enterprise Value for Today is ¥10,010 Mil.
Shanghai Medicilon (SHSE:688202) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Shanghai Medicilon Market Cap Related Terms
Shanghai Medicilon Market Cap Historical Data
* Premium members only.
The historical data trend for Shanghai Medicilon's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688202 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Shanghai Medicilon's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Medicilon Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Medicilon's Market Cap distribution charts can be found below:
* The bar in red indicates where Shanghai Medicilon's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Shanghai Medicilon's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Medicilon (SHSE:688202) has a Market Cap of ¥10,164 Mil as of Jul. 08, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Shanghai Medicilon and its competitors. According to the industry distribution chart, Shanghai Medicilon ranks #225 out of 1420 companies in the Biotechnology industry, placing it in the top 15.8%.
Is Shanghai Medicilon's Market Cap too high?
Shanghai Medicilon's current Market Cap is ¥10,164 Mil. Based on the distribution chart, Shanghai Medicilon ranks #225 out of 1420 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Medicilon has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Medicilon's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Medicilon ranks #225 out of 1420 companies for Market Cap. This places Shanghai Medicilon in the top 16% of its industry — outperforming the majority of peers. The industry median Market Cap is 121.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.52, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Shanghai Medicilon and its competitors. For the Biotechnology industry, the median Market Cap is 121.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Medicilon's current Market Cap is ¥10,164 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Medicilon stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Medicilon (SHSE:688202) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥45.91, compared to a current price of ¥75.65 — trading 64.8% above its estimated fair value. The current Market Cap is ¥10,164 Mil. Shanghai Medicilon's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Shanghai Medicilon (SHSE:688202), the current Market Cap is ¥10,164 Mil as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Medicilon (SHSE:688202) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Medicilon stock appears to be overvalued.
The current stock price of ¥75.65 is trading 64.8% above its estimated GF Value™ of ¥45.91.
GuruFocus considers Shanghai Medicilon to be Significantly Overvalued.
Key valuation signals for SHSE:688202:
Market Cap: ¥10,164 Mil
GF Value™: ¥45.91 vs. price of ¥75.65 (64.8% above fair value)
No single metric tells the full story. See the SHSE:688202 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.
70GF Score
Get the complete analysis for SHSE:688202
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688202 has been successfully added to your 
